Competition from generics are hurting Zoloft, Norvasc and Lipitor sales. Torcetrapib was supposed to save them – but now the pipeline looks pretty empty.
Generics are killing Pfizer
More in Uncategorized
Past Week
-
Elite access vs. public scrutiny: Medication disparities exposed
-
Talk to your patients about money
-
Too many older adults are taking risky sedative medications
-
The Supreme Court must consider science, not pseudo-science, in public health rulings
-
Navigating organizational dysfunction: lessons from Boeing
-
The Change Healthcare hack: a wake-up call for the health care industry
-
Past 6 Months
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Elite access vs. public scrutiny: Medication disparities exposed
-
The abuser’s playbook: the weaponization of mental health
-
Real pain deserves real treatment
-
Physician burnout: a surgeon’s story of exhaustion, recovery, and systemic change
-
From fear of loneliness to embracing solitude
-
Recent Posts
-
The Change Healthcare hack: a wake-up call for the health care industry
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
Working patients and health care [PODCAST]
-
Preventing amputations and saving lives starts with bringing PAD into the 21st century
-
Optimizing IUD placement: prescribed medications and timing tips
-
AI’s role in simplifying communication [PODCAST]
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
